Clinical Trial Update: Ablation Combined With PD-1 in HCC: Phase II Study [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating ablation combined with PD-1 blockade for hepatocellular carcinoma (HCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 inhibitor
• ablation

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN